- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Trial Details

NCT ID

NCT06856837

Phase

PHASE2

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• Fruquintinib
• Tislelizumab
• Trifluridine/tipiracil
• Bevacizumab

Locations (sample)

• Linz, Austria|48.30639,14.28611
• Salzburg, Austria|47.79941,13.04399
• Wiener Neustadt, Austria|47.80485,16.23196
• Amberg, Germany|49.44287,11.86267
• Bad Saarow, Germany|52.28333,14.06667

Key Eligibility Criteria

• Patient\* provide signed informed consent form.
• Patient is ≥ 18 years at the time of given informed consent.
• Patient has been diagnosed with histologically or cytologically proven microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic ade…
• Known RAS (KRAS or NRAS) and BRAF V600E mutational status. Note: These mutations are mutually exclusive. Therefore, if one of the factors is mutate…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.